Castlight Health Announces Fourth Quarter and Full Year 2020 Results

<br /> Castlight Health Announces Fourth Quarter and Full Year 2020 Results<br />

PR Newswire


SAN FRANCISCO

, Feb. 23, 2021 /PRNewswire/ — Castlight Health, Inc. (NYSE:CSLT), a leading health benefits platform provider, today announced results for its fourth quarter and full year ended December 31, 2020.

“Our strong fourth quarter performance punctuated an important year for Castlight, during which we achieved a number of strategic milestones and delivered Castlight’s best financial performance in the company’s history,” said

Maeve O’Meara

, chief executive officer of Castlight Health. “We accomplished several key achievements in the quarter, including adding a new health plan customer, Blue Cross Blue Shield of

Alabama

, in December, signing a partnership with Boston Children’s Hospital to support the national vaccination effort, and delivering strong results from our first year live with Care Guides. Our swift decisions early in the year strengthened our financial position, but still enabled us to address our customers’ needs amidst the pandemic. We are confident that the foundation we have built in high-tech, high-touch navigation has us well positioned to capture share in the growing market and deliver ARR growth in 2021.”

Financial performance for the three months ended December 31, 2020 compared to the three months ended December 31, 2019 includes:

  • GAAP total revenue of

    $37.1 million

    , compared to

    $36.4 million
  • GAAP gross margin of 65.2%, compared to 55.3%
  • Non-GAAP gross margin of 68.0%, compared to 57.8%
  • GAAP operating loss of

    $1.4 million

    , compared to

    $12.2 million
  • Non-GAAP operating income of

    $2.7 million

    , compared to an operating loss of

    $8.1 million
  • GAAP net loss per basic and diluted share of

    $0.01

    , compared to a net loss per basic and diluted share of

    $0.08
  • Non-GAAP net income per basic and diluted share of

    $0.02

    , compared to a net loss per basic and diluted share of

    $0.05
  • Cash provided by operations of

    $3.0 million

    , compared to

    $4.0 million

Financial performance for the 12 months ended December 31, 2020 compared to the 12 months ended December 31, 2019 includes:

  • GAAP total revenue of

    $146.7 million

    , compared to

    $143.3 million
  • GAAP gross margin of 64.5%, compared to 58.8%
  • Non-GAAP gross margin of 67.5% compared to 61.6%
  • GAAP operating loss of

    $62.8 million

    , compared to a loss of

    $41.3 million
  • Non-GAAP operating income of

    $6.3 million

    , compared to a loss of

    $21.7 million
  • GAAP net loss per basic and diluted share of

    $0.41

    , compared to a net loss per basic and diluted share of

    $0.28
  • Non-GAAP net income per basic and diluted share of

    $0.05

    , compared to a net loss per basic and diluted share of

    $0.14
  • Cash used in operations of

    $5.6 million

    , compared to

    $17.4 million

    used in operations

Total cash and cash equivalents were

$49.2 million

as of December 31, 2020.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”


Business Outlook

For the full year 2021, the Company expects:

  • GAAP revenue in the range of

    $130 million

    and

    $135 million
  • Non-GAAP operating loss between

    $4 million

    and

    $9 million
  • Non-GAAP net loss per share between

    $0.02

    and

    $0.06

    , based on approximately 160 million to 161 million shares

For the first quarter of 2021, the Company expects:

  • GAAP revenue in the range of

    $32 million

    and

    $34 million


Quarterly Conference Call

Castlight Health senior management will host a conference call to discuss its fourth quarter and full year 2020 results and business outlook today at

2:00 p.m. Pacific Time

(

5:00 p.m. Eastern Time

). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the Company’s Investor Relations website at

http://ir.castlighthealth.com

. An archive of the webcast can also be accessed through the same link. The live conference call can be accessed by dialing (833) 238-7953 and the replay will be available for one week at (800) 585-8367. The conference ID number for the live call and replay is 4576726.


About Castlight Health

Castlight is on a mission to make it as easy as humanly possible for its users to navigate the healthcare system and live happier, healthier, more productive lives. Our health navigation platform connects hundreds of health vendors, benefits resources, and plan designs into one comprehensive health and wellbeing experience. We guide individuals—based on their unique profile—to the best resources available to them, whether they are healthy, chronically ill, or actively seeking medical care. Castlight transforms the employee benefit experience into a deeply personalized, yet simple, guided one, empowering better-informed patient decisions to unlock better healthcare outcomes and maximizing return on healthcare investments.

For more information visit


www.castlighthealth.com


.  Follow us on

Twitter

and

LinkedIn

and Like us on

Facebook

.


Non-GAAP Financial Measures

To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP net income (loss) per share. Non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), and non-GAAP net income (loss) exclude goodwill impairment, stock-based compensation, certain legal expenses, amortization of intangibles, restructuring charges, capitalization and amortization of internal-use software, and lease exit and related charges.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance. However, these non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP.

The non-GAAP measures we provide may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the Company’s financial information in its entirety and not rely on a single financial measure.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP (i) operating loss and net loss per share guidance for the full year 2021 to comparable GAAP measures because we do not provide guidance for stock-based compensation expense, and (ii) capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP. The factors that may impact our future stock-based compensation expense, and capitalization and amortization of internal-use software, are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort. Factors include our market capitalization and related volatility of our stock price and our inability to project the cost or scope of internally produced software.


Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Words such as “anticipates,” “expects,” “intends,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “can,” “may,” “will,” “would” and similar expressions identify such forward-looking statements. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. The forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies include, but are not limited to, statements regarding certain 2021 projections, the impact of COVID-19, the success of our strategy, and our expectations for our future business and financial performance. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s Annual Report on Form 10-K and other documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified in their entirety by these cautionary statements and are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements, except as required by law.

Copyright 2021 Castlight Health, Inc.

Castlight Health


®

is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.



CASTLIGHT HEALTH, INC.



CONDENSED CONSOLIDATED BALANCE SHEETS



(In thousands)



(unaudited)



As of



December 31, 2020



December 31, 2019


Assets


Current assets:


Cash and cash equivalents


$


49,242


$


43,017


Marketable securities




16,411


Accounts receivable and other, net


31,740


31,397


Prepaid expenses and other current assets


3,800


4,645


Total current assets


84,782


95,470


Property and equipment, net


5,321


4,856


Restricted cash, non-current


1,144


1,144


Deferred commissions


9,556


14,718


Deferred professional service costs


4,462


6,711


Intangible assets, net


7,930


12,178


Goodwill


41,485


91,785


Operating lease right-of-use assets, net


10,238


13,906


Other assets


1,855


2,016


Total assets


$


166,773


$


242,784


Liabilities and stockholders’ equity


Current liabilities:


Accounts payable


$


5,145


$


19,596


Accrued expenses and other current liabilities


7,898


10,454


Accrued compensation


8,633


8,770


Deferred revenue


6,848


10,173


Operating lease liabilities


5,789


5,914


Total current liabilities


34,313


54,907


Deferred revenue, non-current


663


572


Debt, non-current




1,395


Operating lease liabilities, non-current


7,446


11,823


Other liabilities, non-current


485


1,213


Total liabilities


42,907


69,910


Stockholders’ equity


123,866


172,874


Total liabilities and stockholders’ equity


$


166,773


$


242,784



CASTLIGHT HEALTH, INC.



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS



(In thousands, except per share data)



(unaudited)



Three Months Ended December 31,



Year Ended December 31,



2020



2019



2020



2019


Revenue:


Subscription


$


34,419


$


34,723


$


141,160


$


137,393


Professional services and other


2,667


1,724


5,549


5,915


Total revenue, net


37,086


36,447


146,709


143,308


Cost of revenue:


Cost of subscription

(1)


7,932


9,150


34,996


34,067


Cost of professional services and other

(1)


4,989


7,150


17,046


25,007


Total cost of revenue


12,921


16,300


52,042


59,074


Gross profit


24,165


20,147


94,667


84,234


Operating expenses:


Sales and marketing

(1)


7,713


10,664


32,026


38,597


Research and development

(1)


11,418


14,487


49,465


58,994


General and administrative

(1)


6,405


7,238


25,662


27,981


Goodwill impairment






50,300




Total operating expenses


25,536


32,389


157,453


125,572


Operating loss


(1,371)


(12,242)


(62,786)


(41,338)


Other income, net


174


496


603


1,336


Net loss


$


(1,197)


$


(11,746)


$


(62,183)


$


(40,002)


Net loss per share, basic and diluted


$


(0.01)


$


(0.08)


$


(0.41)


$


(0.28)


Weighted-average shares used to compute

basic and diluted net loss per share


154,739


147,359


151,478


145,172


(1)


Includes stock-based compensation expense as follows:



Three Months Ended December 31,



Year Ended December 31,



2020



2019



2020



2019


Cost of revenue:


Cost of subscription


$


215


$


179


$


813


$


774


Cost of professional services and other


219


216


650


953


Sales and marketing


326


175


2,028


2,142


Research and development


1,041


1,369


4,544


6,100


General and administrative


1,085


1,217


4,410


5,034



CASTLIGHT HEALTH, INC.



CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS



(In thousands)



(unaudited)



Three Months Ended December 31,



Year Ended December 31,



2020



2019



2020



2019


Operating activities:


Net loss


$


(1,197)


$


(11,746)


$


(62,183)


$


(40,002)


Adjustments to reconcile net loss to net cash used in

operating activities:


Depreciation and amortization


1,630


1,552


6,537


5,920


Goodwill impairment






50,300




Stock-based compensation


2,886


3,156


12,445


15,003


Amortization of deferred commissions


2,272


3,365


7,789


10,768


Amortization of deferred professional service costs


1,100


2,132


3,517


5,242


Non-cash operating lease expense


1,145


1,396


4,910


5,315


Accretion and amortization of marketable securities




6


2


(238)


Changes in operating assets and liabilities:


Accounts receivable and other, net


(1,269)


4,045


(343)


(4,581)


Deferred commissions


(1,231)


(841)


(2,627)


(5,344)


Deferred professional service costs


(260)


(385)


(1,178)


(1,686)


Prepaid expenses and other assets


582


924


824


102


Accounts payable


426


6,900


(13,622)


9,278


Operating lease liabilities


(1,558)


(1,459)


(5,744)


(5,726)


Accrued expenses and other liabilities


(245)


(688)


(2,821)


(3,760)


Deferred revenue


(3,134)


(7,588)


(3,234)


(10,478)


Accrued compensation


1,812


3,223


(137)


2,795


Net cash provided by (used in) operating activities


2,959


3,992


(5,565)


(17,392)


Investing activities:


Purchase of property and equipment


(149)


(1,241)


(3,580)


(1,953)


Purchase of marketable securities




(7,520)


(2,994)


(30,589)


Sales of marketable securities






2,001




Maturities of marketable securities




11,075


17,400


25,745


Net cash (used in) provided by investing activities


(149)


2,314


12,827


(6,797)


Financing activities:


Proceeds from exercise of stock options


92


1,136


270


3,060


Proceeds from ESPP offering






371




Principal payments on long-term debt


(464)


(465)


(1,859)


(1,859)


Net cash (used in) provided by financing activities


(372)


671


(1,218)


1,201


Net increase (decrease) in cash, cash equivalents and

restricted cash


2,438


6,977


6,044


(22,988)


Cash, cash equivalents and restricted cash at beginning of

period


47,948


37,365


44,342


67,330


Cash, cash equivalents and restricted cash at end of

period


$


50,386


$


44,342


$


50,386


$


44,342


Reconciliation of cash, cash equivalents and restricted

cash:


Cash and cash equivalents


$


49,242


$


43,017


$


49,242


$


43,017


Restricted cash included in Prepaid and other current

assets




181




181


Restricted cash, non-current


1,144


1,144


1,144


1,144


Total cash, cash equivalents and restricted cash


$


50,386


$


44,342


$


50,386


$


44,342



CASTLIGHT HEALTH, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(In thousands, except per share data)

(unaudited)



Three Months Ended



Year Ended



December 31, 2020



September 30, 2020



December 31, 2019



December 31, 2020



December 31, 2019



Gross profit:


GAAP gross profit subscription


$


26,487


$


26,056


$


25,573


$


106,164


$


103,326


Stock-based compensation


215


224


179


813


774


Amortization of internal-use software


80


79




264




Amortization of intangibles


530


530


530


2,120


2,364


Reduction in workforce








221




Non-GAAP gross profit subscription


$


27,312


$


26,889


$


26,282


$


109,582


$


106,464


GAAP gross margin subscription


77.0


%


76.5


%


73.6


%


75.2


%


75.2


%


Non-GAAP gross margin subscription


79.4


%


78.9


%


75.7


%


77.6


%


77.5


%


GAAP gross loss professional services


$


(2,322)


$


(2,865)


$


(5,426)


$


(11,497)


$


(19,092)


Stock-based compensation


219


171


216


650


953


Reduction in workforce








317




Non-GAAP gross loss professional services


$


(2,103)


$


(2,694)


$


(5,210)


$


(10,530)


$


(18,139)


GAAP gross margin professional services


(87)


%


(284)


%


(315)


%


(207)


%


(323)


%


Non-GAAP gross margin professional services


(79)


%


(267)


%


(302)


%


(190)


%


(307)


%


GAAP gross profit


$


24,165


$


23,191


$


20,147


$


94,667


$


84,234


Impact of non-GAAP adjustments


1,044


1,004


925


4,385


4,091


Non-GAAP gross profit


$


25,209


$


24,195


$


21,072


$


99,052


$


88,325


GAAP gross margin


65.2


%


66.1


%


55.3


%


64.5


%


58.8


%


Non-GAAP gross margin


68.0


%


69.0


%


57.8


%


67.5


%


61.6


%



Operating expense:


GAAP sales and marketing


$


7,713


$


6,158


$


10,664


$


32,026


$


38,597


Stock-based compensation


(326)


(282)


(175)


(2,028)


(2,142)


Amortization of intangibles


(528)


(528)


(529)


(2,112)


(1,601)


Reduction in workforce




2




(332)




Non-GAAP sales and marketing


$


6,859


$


5,350


$


9,960


$


27,554


$


34,854


GAAP research and development


$


11,418


$


11,182


$


14,487


$


49,465


$


58,994


Stock-based compensation


(1,041)


(1,026)


(1,369)


(4,544)


(6,100)


Reduction in workforce




(5)




(663)




Certain legal expenses








191


(191)


Capitalization of internally developed software






80


21


80


Non-GAAP research and development


$


10,377


$


10,151


$


13,198


$


44,470


$


52,783


GAAP general and administrative


$


6,405


$


6,341


$


7,238


$


25,662


$


27,981


Stock-based compensation


(1,085)


(1,401)


(1,217)


(4,410)


(5,034)


Amortization of intangibles






(16)


(17)


(66)


Certain legal expenses










(533)


Reduction in workforce




15




(482)




Non-GAAP general and administrative


$


5,320


$


4,955


$


6,005


$


20,753


$


22,348


GAAP goodwill impairment


$




$




$




$


50,300


$




Goodwill impairment








(50,300)




Non-GAAP goodwill impairment


$




$




$




$




$




GAAP operating expense


$


25,536


$


23,681


$


32,389


$


157,453


$


125,572


Impact of non-GAAP adjustments


(2,980)


(3,225)


(3,226)


(64,676)


(15,587)


Non-GAAP operating expense


$


22,556


$


20,456


$


29,163


$


92,777


$


109,985



Operating loss:


GAAP operating loss


$


(1,371)


$


(490)


$


(12,242)


$


(62,786)


$


(41,338)


Impact of non-GAAP adjustments


4,024


4,229


4,151


69,061


19,678


Non-GAAP operating income (loss)


$


2,653


$


3,739


$


(8,091)


$


6,275


$


(21,660)



Net loss and net loss per share:


GAAP net loss


$


(1,197)


$


(447)


$


(11,746)


$


(62,183)


$


(40,002)


Total pre-tax impact of non-GAAP adjustments


4,024


4,229


4,151


69,061


19,678


Non-GAAP net income (loss)


$


2,827


$


3,782


$


(7,595)


$


6,878


$


(20,324)


GAAP net loss per share, basic and diluted


$


(0.01)


$




$


(0.08)


$


(0.41)


$


(0.28)


Non-GAAP net income (loss) per share, basic and diluted


$


0.02


$


0.02


$


(0.05)


$


0.05


$


(0.14)


Shares used in basic and diluted net loss per share computation


154,739


152,146


147,359


151,478


145,172


Castlight Media Contact:



Caroline Kawashima



[email protected]


415-246-0313


Castlight Investor Contact:



[email protected]


443-213-0500

Cision
View original content to download multimedia:

http://www.prnewswire.com/news-releases/castlight-health-announces-fourth-quarter-and-full-year-2020-results-301233870.html

SOURCE Castlight Health, Inc.